ABSTRACT
Polymorphisms in the human leukocyte antigen (HLA) genes within the major histocompatibility complex (MHC) locus strongly influence autoimmune disease risk1–5. Two non-exclusive hypotheses exist about the pathogenic role of HLA alleles; i) the central hypothesis, where HLA risk alleles influence thymic selection so that the probability of T cell receptors (TCRs) reactive to pathogenic antigens is increased6–8; and ii) the peripheral hypothesis, where HLA risk alleles increase the affinity for pathogenic antigens9–11. The peripheral hypothesis has been the main research focus in autoimmunity, while human data on the central hypothesis are lacking. Here, we investigated the influence of HLA alleles on TCR composition at the highly diverse complementarity determining region 3 (CDR3), where TCR recognizes antigens. We demonstrated unexpectedly powerful HLA-CDR3 associations. The strongest association was found at HLA-DRB1 amino acid position 13 (n = 628 subjects, explained variance = 9.4%; P = 4.1 x 10−138). This HLA position mediates genetic risk for multiple autoimmune diseases. In structural analysis of TCR-peptide-MHC complexes, we observed that HLA-DRB1 position 13 does not interact directly with CDR3, but is proximate to antigenic peptide residues that are also close to CDR3. We identified multiple CDR3 amino acid features enriched by HLA risk alleles; for example, the risk alleles of rheumatoid arthritis, type 1 diabetes, and celiac disease all increase the hydrophobicity of CDR3 position 109 (P < 2.1 x 10−5). In the setting of celiac disease, the CDR3 features favored by HLA risk alleles are more enriched among candidate pathogenic TCRs than control TCRs (P = 2.4 × 10−6 for gliadin specific TCRs). Together, these results provide novel genetic evidence supporting the central hypothesis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by funding from the National Institutes of Health (AR063759-05 (SR), U01-HG009379-04 (SR), U19-AI111224-06 (SR), T32GM007753 (KL)). K.I was supported by The Uehara Memorial Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We followed our institutional IRB guidelines.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All raw TCR sequence data and genotype data of the discovery dataset and the replication dataset are available at Adaptive Biotechnologies immuneACCESS site and European Genome-phenome Archive under the accession code of EGAD00001002671 and EGAD00001002663. All summary statistics of cdr3-QTL analysis are available at our website.
